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We conducted a meta-
analysis of overall survival in
3795 patients with non-
small cell lung cancer who
were randomized in 21 trials
comparing higher versus
lower radiation therapy doses
of curative intent. In trials
with chemotherapy, higher
radiation therapy doses led to
poorer survival, but in trials
where chemotherapy was not
given, higher time-corrected
biologically equivalent doses
resulted in longer survival.
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http://dx.doi.org/10.1016/j.ijrobp.2016.07.022Purpose: The optimum dose and fractionation in radiation therapy of curative intent
for non-small cell lung cancer remains uncertain. We undertook a published data
meta-analysis of randomized trials to examine whether radiation therapy regimens
with higher time-corrected biologically equivalent doses resulted in longer survival,
either when given alone or when given with chemotherapy.
Methods and Materials: Eligible studies were randomized comparisons of 2 or more
radiation therapy regimens, with other treatments identical. Median survival ratios
were calculated for each comparison and pooled.
Results: 3795 patients in 25 randomized comparisons of radiation therapy dose were
studied. The median survival ratio, higher versus lower corrected dose, was 1.13 (95%
confidence interval [CI] 1.04-1.22) when radiation therapy was given alone and 0.83
(95% CI 0.71-0.97) when it was given with concurrent chemotherapy (P for differen-
ceZ.001). In comparisons of radiation therapy given alone, the survival benefit
increased with increasing dose difference between randomized treatment arms (P
for trendZ.004). The benefit increased with increasing dose in the lower-dose arm
(P for trendZ.01) without reaching a level beyond which no further survival benefit
was achieved. The survival benefit did not differ significantly between randomized
comparisons where the higher-dose arm was hyperfractionated and those where it
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escalation within the context
of toxicity reduction.(P<.001), average age at randomization (P<.001), and year trial started (P for
trendZ.004), but not for proportion of patients with squamous cell carcinoma (PZ.2).
Conclusions: In trials with concurrent chemotherapy, higher radiation therapy doses
resulted in poorer survival, possibly caused, at least in part, by high levels of toxicity.
Where radiation therapy was given without chemotherapy, progressively higher radi-
ation therapy doses resulted in progressively longer survival, and no upper dose level
was found above which there was no further benefit. These findings support the
consideration of further radiation therapy dose escalation trials, making use of modern
treatment methods to reduce toxicity.  2016 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).Introduction
Lung cancer is the most common cause of cancer death
worldwide, and survival has improved little since the mid-
1970s, with 10-year survival at only 4% in 2011 (1, 2).
Almost 90% of lung cancers are non-small cell (NSCLC)
(3), and surgery is the main curative treatment. Many pa-
tients are, however, inoperable at presentation (4), and for
them, radiation therapy of curative intent may be considered,
possibly in conjunction with chemotherapy. Since the 1970s,
conventional radiation therapy in NSCLC has been defined
as 60 to 63 Gy in 1.8- to 2.0-Gy fractions (5-7), but several
trials have considered alternatives. These include split-
course radiation therapy (with a several-day break), hyper-
fractionation (multiple smaller daily doses), hypofractiona-
tion (fewer, larger-dose fractions), acceleration (delivering
the same dose over a shorter period), or changing total dose
while keeping the same dose per fraction. Changes to these
parameters all affect the biologically effective dose (BED)
and may alter tumor control probability.
No randomized trials of radiation therapy dose and
fractionation in NSCLC have included more than 600 pa-
tients, and many include fewer than 200. Consequently,
most have not, individually, had sufficient power to detect
modest effects on survival that would be important clini-
cally. Where significant effects have been seen in individual
trials, they may reflect extremes in the play of chance. More
powerful inferences can be obtained when the data from all
trials addressing a particular question are combined in a
meta-analysis. Several meta-analyses of trials comparing
different radiation therapy regimens in NSCLC have been
conducted (8-10), but none has evaluated the effect of ra-
diation therapy in terms of different levels of BED, and
none has included all the relevant trials.
Several randomized trials have addressed the role of
chemotherapy in addition to radiation therapy in NSCLC
(11, 12). A Cochrane review of 3752 patients in 25 trials
concluded that concurrent chemoradiation therapy resulted
in better survival than radiation therapy alone (hazard ratio
[HR], chemotherapy vs not: HR 0.71, 95% CI 0.64-0.80) or
radiation therapy with sequential chemotherapy (HR 0.74,
95% CI 0.62-0.89) (13). Therefore, over the past decade,
this has become the standard of care for patients withlocally advanced NSCLC. However, patients treated with
chemoradiation therapy experience more toxicity than do
those treated with radiation therapy alone, particularly
when chemotherapy is given concurrently (7, 13). Thus,
within the context of chemoradiation, radiation dose esca-
lation may result in a level of toxicity that outweighs any
benefit from improved tumor control.
Given the ongoing uncertainty regarding the optimal
dose for curative-intent radiation therapy for NSCLC, and
the high levels of toxicity, it is not surprising that radiation
therapy practice varies (12, 14, 15). Recent advances are,
however, enabling radiation therapy to be delivered with
lower toxicity than previously, so knowledge regarding the
optimal dose for curative-intent radiation therapy is
becoming more important. We have, therefore, conducted a
meta-analysis of published data from randomized trials
comparing different radiation therapy regimens. Our aim
was to examine whether radiation therapy regimens deliv-
ering a higher corrected dose increased the overall survival
in curative-intent radiation therapy for NSCLC, either when
given alone or with chemotherapy.
Methods and Materials
Literature search and selection criteria
The Embase database was searched, using variations of the
terms radiation therapy dose fractionation, hyper-
fractionation, hypofractionation, accelerated radiation
therapy, and lung cancer (Fig. E1; available online at www
.redjournal.org). Studies starting between 1980 and April
28, 2015, were eligible if they included a randomized
comparison of 2 or more external beam radiation therapy
dose fractionation regimens, with other treatments identical
in any arms compared. A trial using hospital numbers to
randomize was excluded (16).
Calculation of time-corrected equivalent dose in 2-
Gy fractions
To compare different dose fractionation regimens, total
doses were converted to time-corrected equivalent doses in
2-Gy fractions (EQD2T) as follows (17):
Ramroth et al. International Journal of Radiation Oncology  Biology  Physics738EQD2TZ
BED
1þ 2a=b
where a/b was assumed to be 10 and BED was defined as
BEDZNd

1þ d
a=b

 kT  Tdelay
where NZnumber of fractions; d Z dose per fraction;
k Z biologic dose needed to compensate for repopulation,
which was assumed to be 0.6 Gy; TZ total treatment time
in days; and Tdelay Z time until onset of repopulation,
assumed to be 21 days. For regimens lasting less than
21 days, k was set to zero (17).
Statistical analyses
Analyses were based on median survival times (18),
extracted from trial publications for each arm. If not re-
ported, they were derived from survivor function graphs or
1-year survival. For each randomized comparison, a median
survival ratio was calculated by dividing median survival in
the higher-dose arm by median survival in the lower-dose
arm. For trials with more than 2 study arms, separate me-
dian survival ratios compared with the lowest-dose arm
were calculated for every other trial arm, resulting in
separate treatment comparisons. Confidence intervals and
significance tests were based on standard errors (19). All
analyses were conducted in Stata version 13.0 (20). Further
methodologic details are in Figure E2 (available online at
www.redjournal.org).Articles on randomized trials: 74
Number of separate trials: 53
Articles after duplicates removed: 4665
Included in meta-analysis:
Randomized trials of curative intent: 21
Number of patients: 3795
Articles identified through
database searching: 4933 
Additional art
identified through
 list searching
Fig. 1. Trial identification and selection.)Reference lists in pub
analyses of radiation therapy in lung cancer were searched to idenResults
Twenty-one trials with 3795 patients were included in
the meta-analysis (Fig. 1) (6, 21-40). Eight trials were
conducted in China, 7 in North America, 4 in Europe, 1
in South Asia, and 1 in Australia (Table 1). (For further
details of study characteristics and treatments, see
Tables E1 and E2; available online at www.redjournal
.org.)
The number of patients in each trial ranged from 30 to
563, the years of randomization from 1982 to 2011, and
the average age at randomization from 48 to 66 years
(Table E1; available online at www.redjournal.org). In the
18 trials reporting proportions of patients by cancer stage,
13 reported that at least 94% of patients had stage III
disease, and 5 reported that between 55% and 89% had
stage III disease. Two trials had multiple arms, resulting
in 25 randomized radiation therapy dose comparisons in
21 trials (Table 1). The EQD2T doses within trial arms
ranged from 36.4 Gy to 80.8 Gy (Table E2; available
online at www.redjournal.org), and EQDT2 increased
with calendar year (PZ.04) (Fig. E3; available online at
www.redjournal.org). The dose difference between trial
arms ranged from 1.1 Gy to 27.2 Gy (Table 1), and in 12
of the randomized comparisons, dose escalation was
achieved by hyperfractionation. Chemotherapy was given
in 7 trials (2 sequential, 5 concurrent) and was not given
in 18. The median survival times ranged from 6.3 to
29.9 months.Articles excluded as not randomized trials 
in lung cancer radiotherapy: 4594
Trials excluded: 32
Palliative non-small cell: 15
Small-cell: 7
Study arms differed in terms of non-
radiotherapy treatment: 5
Same time-corrected biologically effective
radiotherapy dose in both arms: 1
Brachytherapy: 1
Stereotactic radiotherapy: 1
Pre-1980s: 1
Non-standard randomization: 1
icles 
 reference
: 13*
lications for all trials included in the study and for othermeta-
tify additional publications of trials missed in the search.
Table 1 Descriptive summary of trials included in meta-analysis, by ascending EQD2T difference between trial arms*
Trial
no.
Study, y
(reference)
Years of
randomization Country
No. of
patients
EQD2T in each
trial arm (Gy)
EQD2T difference
between trial
arms (Gy) Chemotherapy
1 Zhan et al,
2007 (39)
2000-2005 China 159 A: 56.2, B: 54.9,
C: 53.8
1.1, 2.4y Concurrent
2 Saunders et al,
1999 (23)
1990-1995 UK, Germany,
Sweden
563 A: 51.8, B: 49.7 2.1 None
3 Schild et al,
2002 (24)
1994-1999 USA 234 A: 49.7, B: 47.2 2.5 Concurrent
4 Bonner et al,
1998 (25)
1992-1993 USA 67 A: 49.7, B: 47.2 2.5 None
5 Cox et al,
1990 (26)
1983-1987 USA 516 A: 61.5, B: 58.4,
C: 55.4, D: 52.3,
E: 49.2
3.1, 6.2, 9.2, 12.3z None
6 Slawson et al,
1988 (27)
1982-1986 USA 120 A: 49.7, B: 46.5 3.2 None
7 Baumann et al,
2011 (21)
1997-2005 Germany, Poland,
Czech Republic
406 A: 57.5, B: 53.6 3.9 None
8 Fu et al,
1994 (28)
1990-1992 China 105 A: 52.3, B: 48.3 4.0 None
9 Belani et al,
2005 (29)
1998-2001 USA 119 A: 55.7, B: 51.6 4.1 Sequential
10 Sapkota et al,
2013 (30)
Not specified India, Nepal 30 A: 54.2, B: 49.7 4.5 Concurrent
11 Sause et al,
2000 (31)
1989-1992 USA, Canada 301 A: 55.4, B: 49.7 5.7 None
12 Reinfuss et al,
1999 (32)
1992-1996 Poland 160 A: 43.2, B: 36.4 6.8 None
13 Zajusz et al,
2006 (36)
2001-2006 Poland 53 A: 61.3, B: 53.5 7.8 None
14 Bradley et al,
2015 (6)
2007-2011 USA, Canada 424 A: 58.8, B: 49.7 9.1 Concurrent
15 Ball et al,
1999 (22)
1989-1995 Australia 99 A: 60.0, B: 49.7 10.3 None
16 Zhu et al,
2000 (40)
1993-1996 China 70 A: 68.8, B: 56.2 12.6 None
17 Cheng W et al,
2007 (38)
1999-2002 China 81 A: 68.8, B: 56.2 12.6 None
18 Cheng J et al,
2004 (37)
1995-1998 China 74 A: 68.8, B: 55.6 13.2 None
19 Wang et al,
2005 (33)
2001-2003 China 86 A: 68.8, B: 53.6 15.2 None
20 Yu et al,
2014 (35)
2009-2011 China 60 A: 68.8, B: 53.2 25.6 Sequential
21 Wang et al,
2008 (34)
2004-2006 China 68 A: 80.8, B: 53.6 27.2 None
* EQD2T is calculated in terms of 2-Gy biologically equivalent dose per fraction, corrected for total treatment time. Study arms are presented in order
of ascending difference in EQD2T between trial arms; if there were multiple arms, study number was assigned based on the smallest dose difference.
y Three-arm study. Each of the higher-dose arms was separately compared with the lowest-dose arm as the baseline. Arm B versus C: 1.1-Gy dif-
ference. Arm A versus C: 2.4-Gy difference.
z Five-arm study. Each of the higher-dose arms was separately compared with the lowest-dose arm as the baseline. Arm D versus E: 3.1-Gy difference.
Arm C versus E: 6.2-Gy difference. Arm B versus E: 9.2-Gy difference. Arm A versus E: 12.3-Gy difference.
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The median overall survival ratio, higher versus lower
EQD2T, pooled across all randomized dose comparisons,
was 1.07 (95% CI 1.00-1.15, PZ.05) (Fig. 2). When thesecomparisons were grouped according to whether the pro-
tocol specified no chemotherapy, sequential chemotherapy,
or concurrent chemotherapy the heterogeneity between
these groups was highly significant (PZ.001). The median
survival ratios were 1.13 (95% CI 1.04-1.22, PZ.002)
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with sequential chemotherapy, and 0.83 (95% CI 0.71-0.97,
PZ.02) with concurrent chemotherapy. Hence, radiation
therapy dose escalation led to significantly better survival
for comparisons without chemotherapy but to significantly
poorer survival in comparisons with concurrent
chemotherapy.
For randomized comparisons that included concurrent
chemotherapy, there was no significant heterogeneity be-
tween the median survival ratios (PZ.5), nor was there any
trend with increasing EQD2T difference between arms
(PZ.1). There were only 2 randomized comparisons with
sequential chemotherapy, including 193 patients, so the
confidence intervals were wide.Radiation therapy dose escalation without
chemotherapy
For the 18 radiation therapyeonly comparisons, the median
survival ratio, higher versus lower radiation therapy dose,
was 1.13 (95% CI 1.04-1.22) (Fig. 2). When these com-
parisons were categorized according to dose difference
between trial arms, the pooled median survival ratio for
EQD2T differences of <5 Gy was 1.05 (95% CI 0.94-1.17,
PZ.4), whereas for EQD2T differences of 5 to 10 Gy it
was 1.08 (95% CI 0.94-1.25, PZ.3), and for EQD2T dif-
ferences of >10 Gy, it was 1.47 (95% CI 1.23-1.75,
P<.001) (Fig. 3A). The increasing trend in median survival
ratios across these 3 groups was highly statistically sig-
nificant (P for trendZ.004), providing strong evidence that
without chemotherapy, survival increases with increasing
EQD2T. When the dose comparisons with EQD2T differ-
ences of 10 Gy between trial arms were further divided
into trials in which hyperfractionation was used to escalate
dose versus other trials, the median survival ratios did not
differ significantly (1.60, 95% CI 1.27-2.02, and 1.29, 95%
CI 0.98-1.71, P for differenceZ.2) (Fig. 4A).
When the 18 radiation therapyeonly comparisons were
grouped according to dose in the lower-dose arm into 3
approximately equal-sized groups (Fig. 3B), the median
survival ratio, higher versus lower dose, was 1.01 (95% CI
0.89-1.14, PZ.9) for comparisons where the EQD2T in the
lower-dose arm was <49.5 Gy, whereas for comparisons in
which it was 49.5 to 53.4 Gy, the median survival ratio was
1.17 (95% CI 1.02-1.33, PZ.02), and for comparisons in
which it was 53.5 Gy, it was 1.28 (95% CI 1.10-1.49,
P<.002). So, surprisingly, the median survival ratio
increased progressively with increasing EQD2T in the
lower-dose arm, with an increasing trend across the 3
groups (P for trendZ.01). Even for trials with EQD2T
53.5 Gy in the lower-dose arm, further dose escalation
provided an additional improvement in survival. For the 5
trials in which the dose in the lower-dose arm was EQD2T
53.5 Gy and where the dose difference was EQD2T
>10 Gy, the median survival ratio was 1.87 (95% CI 1.47-
2.38, P<.001). When comparisons with EQD2T 53.5 Gyin the lower-dose arm were categorized into trials in which
hyperfractionation was used to escalate dose versus other
trials, the median survival ratio for the 2 groups was similar
(1.27, 95% CI 1.08-1.51, and 1.32, 95% CI 0.92-1.89, P for
differenceZ.9) (Fig. 4B).
Heterogeneity between trials and exploratory
analyses
The median survival ratios for the 18 radiation ther-
apyeonly dose comparisons varied substantially, from 0.68
(95% CI 0.47-0.99) to 2.28 (95% CI 1.42-3.67) (P for
heterogeneity<.001) (Fig. 2). The difference in EQD2T
between trial arms did not account for all the excess het-
erogeneity, so exploratory analyses were conducted to
examine the associations between median survival ratios
and other available factors (Fig. 5). The median survival
ratio, higher versus lower EQD2T, was higher for trials
conducted in China than for trials conducted elsewhere
(China: 1.85, 95% CI 1.50-2.27; elsewhere: 1.04, 95% CI
0.96-1.13, P for difference <.001) (Fig. 5A), for trials with
lower median age (<60 years: 1.66, 95% CI 1.37-2.02,
60þ years: 1.06 95% CI 0.97-1.17, P for difference <.001)
(Fig. 5B), and for trials starting more recently (1980s: 0.98,
95% CI 0.87-1.11, 1990s: 1.24, 95% CI 1.11-1.38, 2000s:
1.32, 95% CI 0.92-1.89, P for trendZ.004) (Fig. 5C). By
contrast, when the trials were grouped according to whether
most patients had squamous cell carcinoma (SCC), no
significant difference was found (PZ.2) (Fig. 5D).
Geographic region, age, and year trial started were corre-
lated, whereas percentage of patients with SCC was not
highly correlated with any other factor (Table E3; available
online at www.redjournal.org). An analysis adjusting for all
4 factors showed the strongest association between
geographic region and median survival ratio (PZ.008),
with all other factors statistically nonsignificant (Table E4;
available online at www.redjournal.org).
Discussion
This large meta-analysis including 3795 patients in 25
treatment comparisons has, for the first time, brought
together all post-1980 randomized evidence comparing
different curative-intent radiation therapy regimens in
NSCLC. To eliminate the confounding effects of other
treatments, we considered only trials in which other pro-
tocol treatments were identical in both arms. We focused on
median survival ratios in relation to corrected dose (ie,
time-corrected equivalent dose, EQD2T) differences be-
tween trial arms and whether the radiation therapy was
given alone or with chemotherapy.
Radiation therapy without chemotherapy
In 18 trials where no protocol chemotherapy was admin-
istered, radiation therapy dose escalation improved overall
Trial
number*
Dose and fractionation,
higher vs lower trial arms
Median survival ratio, higher vs lower EQD2T† (95% CI)
i) NO chemotherapy
2
4
5iv
6
7
8
11
5iii
12
5ii
13
5i
15
16
17
18
19
21
54 Gy in 36 (hyper, WE) vs 60 Gy in 30
60 Gy in 30 vs 60 Gy in 40 (hyper, split)
64.8 Gy in 54 (hyper) vs 60 Gy in 50 (hyper)
60 Gy in 30 vs 60 Gy in 12 (hypo)
60 Gy in 40 (hyper) vs 66 Gy in 33
69.6 Gy in 58 (hyper) vs 63.9 Gy in ~34
69.6 Gy in 58 (hyper) vs 60 Gy in 30
69.6 Gy in 58 (hyper) vs 60 Gy in 50 (hyper)
50 Gy in 25 vs 40 Gy in 10 (hypo, split)
72 Gy in 40 (WE) vs 72 Gy in 40
74.4 Gy in 62 (hyper) vs 60 Gy in 50 (hyper)
60 Gy in 30 (hyper) vs 60 Gy in 30
79.2 Gy in 66 (hyper) vs 60 Gy in 50 (hyper)
76 Gy in 40 (part hyper) vs 70 Gy in 35
70 Gy in 40 (part hyper) vs 70 Gy in 35
70 Gy in 40 (part hyper) vs 70 Gy in 35
64 Gy in 26 (part hypo) vs 66 Gy in 33
80 Gy in 34 (part hypo) vs 66 Gy in 32
1.27 (1.06-1.52)
0.70 (0.50-1.00)
0.68 (0.47-0.99)
0.84 (0.58-1.20)
1.00 (0.81-1.23)
1.79 (1.20-2.69)
1.05 (0.84-1.32)
1.09 (0.78-1.52)
1.33 (0.96-1.86)
0.97 (0.55-1.72)
0.95 (0.67-1.34)
1.04 (0.70-1.57)
1.14 (0.81-1.62)
1.96 (1.16-3.32)
2.28 (1.42-3.67)
1.71 (1.07-2.72)
1.74 (0.96-3.13)
1.45 (0.68-3.10)
1.13 (1.04-1.22)
2P=.002
1.36 (0.90-2.05)
1.15 (0.65-2.05)
1.29 (0.92-1.80)
2P=.1
0.88 (0.57-1.35)
0.94 (0.59-1.48)
0.93 (0.70-1.23)
1.20 (0.41-3.46)
0.71 (0.55-0.90)
0.83 (0.71-0.97)
2P=.02
1.07 (1.00-1.15)
2P=.05
0.3 0.5 0.8 1.0 1.5 2.0 3.0 4.5
Lower EQD2T† better
All trials in i)
Within-group heterogeneity: X2 = 45.8 on 17 df, P<.001
Within-group heterogeneity: X2 = 3.2 on 4 df, P=.5
9
ii)
iii) Concurrent chemotherapy
Sequential chemotherapy
1ii
1i
3
10
14
68 Gy in 34 (hyper, split) vs 67.2 in 56
67.2 Gy in 42 (hyper) vs 67.2 in 56
60 Gy in 30 vs 60 Gy in 40 (hyper, split)
60 Gy in 40 (hyper) vs 60 Gy in 30 
74 Gy in 37 vs 60 Gy in 30 
57.6 Gy in 36 (hyper) vs 64 Gy in 32
65 Gy in 25 (hypo) vs 60 Gy in 30
All trials in ii) 
All trials in iii) 
All trials in i) + ii) + iii) 
Heterogeneity between i), ii), and iii): X2 = 13.4 on 2 df, P=.001 
Within-group heterogeneity: X2= 0.2 on 1 df, P=.6
20
Higher EQD2T† better
Fig. 2. Median survival ratios, higher versus lower corrected radiation therapy dose (EQD2T), according to whether ra-
diation therapy was given without chemotherapy, with sequential chemoradiation therapy, or with concurrent chemoradiation
therapy. Abbreviations: hyper Z hyperfractionated (>1 fraction per day); hypo Z hypofractionated (>2 Gy per fraction);
part hyper Z partially hyperfractionated; part hypo Z partially hypofractionated; split Z split-course radiation therapy,
minimum 10-day gap; WE Z including weekends. )Studies are ordered within groups by ascending EQD2T difference
between trial arms. yEQD2T is time-corrected equivalent dose in 2-Gy fractions.
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corresponding to a survival gain of approximately 2 months
for patients in these trials. The survival improvement
increased progressively as the difference between EQD2T
in the 2 trial arms increased and, in trials where the dif-
ference was EQD2T >10 Gy, the median survival ratio was
1.47 (95% CI 1.23-1.75). Remarkably, even for trials where
the dose in the lower-dose arm was high (EQD2T
53.5 Gy), further dose escalation provided an additional
improvement in survival (median survival ratio: 1.28, 95%CI 1.10-1.49) (Fig. 3B). In trials with EQD2T 53.5 Gy in
the lower-dose arm where the dose difference exceeded
EQD2T 10 Gy, the median survival ratio was 1.87 (95% CI
1.47-2.38), and for these patients the survival gain was
approximately 1 year.
The commonest method of altering dose and fraction-
ation in these trials was hyperfractionation. Two previous
meta-analyses of different radiation therapy regimens
focused on comparing hyperfractionation or acceleration
with conventional radiation, rather than on corrected dose
Trial
number*
Dose and fractionation,
higher vs lower trial arms
EQD2T† EQD2T† difference, Median survival ratio, higher vs lower EQD2T† (95% CI)
arm 1 vs arm 2 arm 1 - arm 2
EQD2T† difference between trial arms
EQD2T†  in lower-dose arm
A
B
i)
ii) 
iii) 
Dose difference <5 Gy
i) Low dose (<49.5 Gy)
iii) High dose (  53.5 Gy)
ii) Medium dose (49.5-53.4 Gy)
Dose difference 5-10 Gy
All trials in i)
Within-group heterogeneity: X2 = 23.0 on 5 df, P<.001
All trials in ii)
Within-group heterogeneity: X2 = 2.3 on 4 df, P=.7
All trials in iii)
Within-group heterogeneity: X2 = 10.0 on 6 df, P=.1
All trials in iii)
Within-group heterogeneity: X2 = 17.0, P=.009
All trials in i)
Within-group heterogeneity: X2 = 20.7 on 7 df, P=.004
All trials in ii)
Within-group heterogeneity: X2 = 2.0 on 2 df, P=.4
All trials in i) + ii) + iii)
Test for trend across i), ii), and iii): X2 = 8.2 on 1 df, P=.004
Lower EQD2T† Higher EQD2T†better better
All in trials in i) + ii) + iii)
Test for trend across i), ii), and iii): X2 = 6.0 on 1 df, P=.01
Dose difference >10 Gy
2    54 Gy in 36 (hyper, WE) vs 60 Gy in 30
4    60 Gy in 30 vs 60 Gy in 40 (hyper, split)
6    60 Gy in 30 vs 60 Gy in 12 (hypo)
7      60 Gy in 40 (hyper) vs 66 Gy in 33
13    72 Gy in 40 (WE) vs 72 Gy in 40
16    76 Gy in 40 (part hyper) vs 70 Gy in 35
17    70 Gy in 40 (part hyper) vs 70 Gy in 35
18    70 Gy in 40 (part hyper) vs 70 Gy in 35
19    64 Gy in 26 (part hypo) vs 66 Gy in 33
21    80 Gy in 34 (part hypo) vs 66 Gy in 32
0.3 0.5 0.8 1.0 1.5 2.0 3.0 4.5
8    69.6 Gy in 58 (hyper) vs 63.9 Gy in ~34
2       54 Gy in 36 (hyper, WE) vs 60 Gy in 30
11    69.6 Gy in 58 (hyper) vs 60 Gy in 30
15    60 Gy in 30 (hyper) vs 60 Gy in 30
5iii  69.6 Gy in 58 (hyper) vs 60 Gy in 50 (hyper)
4    60 Gy in 30 vs 60 Gy in 40 (hyper,split)
6    60 Gy in 30 vs 60 Gy in 12 (hypo)
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5iv  64.8 Gy in 54 (hyper) vs 60 Gy in 50 (hyper)
>-
51.8 vs 49.7
49.7 vs 47.2
52.3 vs 49.2
49.7 vs 46.5
57.5 vs 53.6
52.3 vs 48.3
55.4 vs 49.7
55.4 vs 49.2
43.2 vs 36.4
61.3 vs 53.5
58.4 vs 49.2
60.0 vs 49.7
61.5 vs 49.2
68.8 vs 56.2
68.8 vs 56.2
68.8 vs 55.6
68.8 vs 53.6
80.8 vs 53.6
49.7 vs 47.2
52.3 vs 49.2
49.7 vs 46.5
52.3 vs 48.3
55.4 vs 49.2
43.2 vs 36.4
58.4 vs 49.2
61.5 vs 49.2
51.8 vs 49.7
55.4 vs 49.7
60.0 vs 49.7
57.5 vs 53.6
61.3 vs 53.5
68.8 vs 56.2
68.8 vs 56.2
68.8 vs 55.6
68.8 vs 53.6
80.8 vs 53.6
3.9
7.8
12.6
12.6
13.2
15.2
27.2
2.1
5.7
10.3
2.5
3.1
3.2
4.0
6.2
6.8
9.2
12.3
2.1
2.5
3.1
3.2
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12.6
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Fig. 3. Median survival ratios, higher versus lower corrected radiation therapy dose (EQD2T). (A) Categorized by EQD2T
difference between arms. (B) Categorized by EQD2T in the lowest-dose arm. Trials with chemotherapy excluded. Abbre-
viations: hyper Z hyperfractionated (>1 fraction per day); hypo Z hypofractionated (>2 Gy per fraction); part hyper Z
partially hyperfractionated; part hypoZ partially hypofractionated; splitZ split-course radiation therapy, minimum 10-day
gap; WE Z including weekends. )Studies are ordered within groups by ascending EQD2T difference between trial arms.
yEQD2T is time-corrected equivalent dose in 2-Gy fractions.
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7 3.9
12.6
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60 Gy in 40 (hyper) vs 66 Gy in 33
10.3
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13.2
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All trials in i)
All trials in i)
i) Hyperfractionation in higher-dose arm
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Heterogeneity between i) and ii): X2 = 1.3 on 1 df, P=.2 
All trials in ii)
All trials in ii)
ii) Other trials
ii) Other trials
13 72 Gy in 40 (WE) vs 72 Gy in 40
All trials in i) + ii) 
Heterogeneity between i) and ii): X2 = 0.03 on 1 df, P=.9 
All trials in i) + ii) 
7.8
15.2
27.2
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1.04 (0.70-1.57)
1.96 (1.16-3.32)
2.28 (1.42-3.67)
1.71 (1.07-2.72)
1.71 (1.07-2.72)
1.60 (1.27-2.02)
1.29 (0.98-1.71)
1.47 (1.23-1.75)
1.28 (1.10-1.49)
1.32 (0.92-1.89)
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2P<.001
2P<.001
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2P=.001
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2P=.005
1.74 (0.96-3.13)
1.74 (0.96-3.13)
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1.00 (0.81-1.23)
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1.96 (1.16-3.32)
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Trial
number*
Dose and fractionation,
higher vs lower trial arms
Median survival ratio,
higher vs lower EQD2T† (95% CI)
EQD2T† difference,
arm 1 - arm 2
A EQD2T† difference between arms is > 10 Gy
B High EQD2T†(≥53.5 Gy) in lower-dose arm
21
64 Gy in 26 (part hypo) vs 66 Gy in 33
80 Gy in 34 (part hypo) vs 66 Gy in 32
19
21
64 Gy in 26 (part hypo) vs 66 Gy in 33
80 Gy in 34 (part hypo) vs 66 Gy in 32
12.3
15.2
27.2
Fig. 4. Median survival ratios, higher versus lower corrected radiation therapy dose (EQD2T), according to whether higher
dose was achieved by hyperfractionation or by other means. (A) Trials with EQD2T >10 Gy dose difference between arms
(ie, group iii in Fig. 3A). (B) Trials with EQD2T in the lower-dose arm 53.5 Gy (ie, group iii in Fig. 3B). Trials with
chemotherapy excluded. Abbreviations: hyperZ hyperfractionated (>1 fraction per day); hypoZ hypofractionated (>2 Gy
per fraction); part hyperZ partially hyperfractionated; part hypoZ partially hypofractionated; splitZ split-course radiation
therapy, minimum 10-day gap; WE Z including weekends. )Studies are ordered within groups by ascending EQD2T
difference between trial arms. yEQD2T is time-corrected equivalent dose in 2-Gy fractions.
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showed a similar improvement in survival regardless of
whether it was achieved by hyperfractionation or by other
means, suggesting that dose escalation may improve sur-
vival regardless of the method used.
Survival improvement from radiation therapy dose
escalation was associated with 3 other factors: younger age,
recent trial start date, and whether the trial was conductedin China. The strongest association was for trials conducted
in China. Nothing in the trial publications indicated that the
Chinese trials differed systematically from other trials, and
inasmuch as the 3 factors were highly correlated, the
geographic association may not be causal. By contrast, it
would not be surprising if radiation therapy dose escalation
had a greater benefit in younger patients, who may be better
able to tolerate radiation therapy than older patients, and
Trial
number*
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number*
Dose and fractionation,
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ii) Trial conducted elsewhere
All trials in iii) 
All trials in ii) 
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Fig. 5. Median survival ratios, higher versus lower corrected radiation therapy dose (EQD2T). (A) According to geographic region. (B) According to median age at
randomization. (C) According to year trial started. (D) According to percentage of patients with squamous cell carcinoma. Trials with chemotherapy excluded. Ab-
breviations: hyper Z hyperfractionated (>1 fraction per day); hypo Z hypofractionated (>2 Gy per fraction); part hyper Z partially hyperfractionated; part
hypo Z partially hypofractionated; split Z split-course radiation therapy, minimum 10-day gap; WE Z including weekends. )Studies are ordered within groups by
ascending EQD2T difference between trial arms. yEQD2T is time-corrected equivalent dose in 2-Gy fractions.
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may also face a lower risk of death resulting from toxicity
than older patients, and have lower competing risks of
death from other causes. Survival improvement was also
greater in more recent trials. This could be due in part to
increased prescribed tumor doses and improved radiation
therapy techniques. There was no significant association
between dose escalation and the percentage of patients with
SCC, but for most trials, the percentage of patients with
SCC was between 40% and 60%, so there was little vari-
ation in this factor.
Radiation therapy with chemotherapy
In trials with concurrent chemotherapy, higher EQD2T led
to poorer overall survival, suggesting that the risks of
increasing radiation therapy dose outweigh the benefits
when concurrent chemotherapy is given (Fig. 2). There was
no evidence of heterogeneity in the median survival ratios
for trials in this group, but the pooled result was dominated
by the RTOG 0617 trial (number 14), in which 207 patients
randomized to EQD2T 58.8 Gy (74 Gy in 37 fractions) had
higher overall mortality than did 217 patients randomized
to EQD2T 49.7 Gy (60 Gy in 30 fractions) (HR, higher vs
lower dose, 1.38, 95% CI 1.09-1.76, PZ.004); the higher-
dose group also had more grade 3 or worse esophageal
toxicity (21% vs 7%, P<.001) (6). The results of this trial
are influencing radiation dose escalation in chemoradiation
therapy, as reflected in the 2015 American Society for
Radiation Oncology guidelines (7); however, there are ar-
guments why this single trial should not stop further
exploration of dose escalation in chemoradiation therapy
(41). One of these is that there was reduced protocol
adherence in the higher-EQD2T arm (higher dose: 153/207
[74%], lower dose: 180/217 [83%], PZ.02), which may
explain the nonsignificantly increased local failure in the
higher-dose group (HR 1.26, 95% CI 0.93-1.71, PZ.1) (6).
Only 2 trials compared different radiation therapy regi-
mens with the same sequential chemotherapy in both arms.
Hence, information on dose escalation with sequential
chemotherapy is limited.
Radiation therapy, chemotherapy, and toxicity
The probability of sterilizing a tumor increases with
increasing tumor radiation dose (42). However, lung cancer
radiation therapy inevitably delivers dose to normal lung
and adjacent organs that may cause pneumonitis, esopha-
gitis, heart disease, and lung fibrosis (43-45). Adding
chemotherapy to radiation therapy further increases
toxicity, including myelosuppression, esophagitis (up to 6
times higher with concurrent chemotherapy), pneumonitis,
and treatment-related death (46). Increasing the irradiated
volume alongside concurrent chemotherapy can also in-
crease toxicity (47). Toxicity is thus a primary constraint in
increasing radiation and chemotherapy dose in NSCLCtreatment, especially because patients often have multiple
comorbidities. In this study, it was not possible to analyze
the effects of toxicity on median survival because of the
variability in toxicity reporting across trials in terms of
type, severity, and time point.
Modern radiation techniques are being developed to
reduce toxicity. They include intensity modulated radiation
therapy, proton beam therapy, and personalized isotoxic
radiation therapy, in which patients receive maximal radia-
tion therapy dose based on normal tissue constraints and
their individual tumor size and location (48). In future, these
efforts to reduce toxicity may facilitate radiation therapy
dose escalation, even when chemotherapy is also given.
Strengths and limitations
Our meta-analysis has several strengths. It is larger and has
more power than previously published meta-analyses of trials
of curative-intent radiation therapy for lung cancer (8-10).We
have, for the first time, examined trials both according to the
corrected radiation therapy dose and to whether chemo-
therapy was delivered. Most importantly, we have included
total treatment time in our dose calculation (EQD2T rather
than EQD2). Omitting the time factor would have resulted in
substantially different results because it would have reversed
the higher and lower dose arms for 7 trials (numbers 2, 6, 7, 9,
10, 17, and 18), and for 2 further trials (numbers 13 and 15) the
corrected doses would have been identical in the 2 arms. This
is because in 7 of these trials, 1 of the arms was hyper-
fractionated (more dose intense) whereas the other was
conventionally fractionated.
The main limitation of our study is a lack of individual
patient data. Effects seen at the aggregate level may be
weaker or stronger than those examined at the individual
level. This also prevented us from considering survival at
2 years, by which time most patients with occult distant
metastases when irradiated would have died. We also could
not conduct analyses of deaths resulting from lung cancer
versus other causes. Another limitation is that the calcula-
tion of EQD2T involves radiobiologic assumptions about
the way in which radiation kills tumor cells, including
values of parameters. For example, in the CHART trial
(number 2), 67% of patients in the higher-dose arm versus
34% in the lower-dose arm experienced severe esophagitis,
although the EQD2T difference to the tumor was calculated
to be only 2.1 Gy (49).
Conclusions
In conclusion, survival in locally advanced NSCLC patients
has seen little improvement over 40 years (2), so any evi-
dence of improvement in survival is clinically important. Our
study shows that when radiation therapy is given without
chemotherapy, escalating radiation therapy dose leads to
improved survival. This suggests that the optimal radiation
dose has yet to be reached, and it provides support for further
Ramroth et al. International Journal of Radiation Oncology  Biology  Physics746trials of dose escalation, especially with modern radiation
therapy techniques that lower toxicity. When chemotherapy
is given with radiation therapy, the ability to achieve a cure
has, until now, been limited by toxicity, especially when it is
given concurrently. Therefore, it may be that the optimal
radiation dose for chemoradiation therapy has also not yet
been reached in the context of new advances, such as
personalized isotoxic dose escalation, and in the continued
search for the optimal concurrent chemotherapy regimen.
Our study therefore also provides support for consideration
of further trials in radiation dose escalation of chemo-
radiation therapy for locally advanced NSCLC.References
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